Aya Mohr-Sasson

Dr. Aya Mohr-Sasson

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Human Reproduction
Verified
Journal Article
Open access
PDF file
AMAya Mohr-Sasson
Aya Mohr-Sasson
JHJ Haas
J Haas
SAS Abuhasira
S Abuhasira
MSM Sivan
M Sivan
HAH Doitch Amdurski
H Doitch Amdurski
JRJ Rabinovici
J Rabinovici
Does the administration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine have an association with ovarian reserve as expressed by circulating anti-Müllerian hormone (AMH) levels? Ovarian reserve as assessed by serum AMH levels is not altered at 3 months following mRNA SARS-CoV-2 vaccination. A possible impact of SARS-CoV-2 infection or vaccination through an interaction between the oocyte and the somatic cells could not be ruled out, however, data are limited. This is a prospective study conducted at a university affiliated tertiary medical center between February and March 2021. Study population included reproductive aged women (18–42 years) that were vaccinated by two Pfizer-BioNTech Covid-19 vaccines (21 days apart). Women with ovarian failure, under fertility treatments, during pregnancy, previous Covid-19 infection or vaccinated were excluded from the study. Blood samples were collected for AMH levels before the first mRNA vaccine administration. Additional blood samples after 3 months were collected for AMH and anti-Covid-19 antibody levels. Primary outcome was defined as the absolute and percentage change in AMH levels. The study group consisted of 129 women who received two mRNA vaccinations. Mean AMH levels were 5.3 (±SD 4.29) µg/l and 5.3 (±SD 4.50) µg/l at baseline and after 3 months, respectively (P = 0.11). To account for possible age-specific changes of AMH, sub-analyses were performed for three age groups: 35 years. AMH levels were significantly lower for women older than 35 years at all times (P = 0.001 for pre and post vaccination AMH levels versus younger women). However, no significant differences for the changes in AMH levels before and after vaccinations (Delta AMH) were observed for the three age groups (P = 0.46). Additionally, after controlling for age, no association was found between the degree of immunity response and AMH levels. Although it was prospectively designed, for ethical reasons we could not assign a priori a randomized unvaccinated control group. This study examined plasma AMH levels at 3 months after the first vaccination. It could be argued that possible deleterious ovarian and AMH changes caused by the SARS-CoV-2 mRNA vaccinations might take effect only at a later time. Only longer-term studies will be able to examine this issue. The results of the study provide reassurance for women hesitant to complete vaccination against Covid 19 due to concerns regarding its effect on future fertility. This information could be of significant value to physicians and patients alike. The study was supported by Sheba Medical Center institutional sources. All authors have nothing to disclose. The study protocol was approved by the ‘Sheba Medical Center’ Ethical Committee Review Board (ID 8121-21-SMC) on 8 February 2021 and was registered at the National Institutes of Health (NCT04748172).

1 June 2020 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
AMAya Mohr-Sasson
Aya Mohr-Sasson
RORaoul Orvieto
Raoul Orvieto
SBShlomit Blumenfeld
Shlomit Blumenfeld
MAMichal Axelrod
Michal Axelrod
DMDanielle Mor-Hadar
Danielle Mor-Hadar
JHJigal Haas
Jigal Haas

22 June 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
AMAya Mohr-Sasson
Aya Mohr-Sasson
JCJennifer Chayo
Jennifer Chayo
YBYossi Bart
Yossi Bart
RMRaanan Meyer
Raanan Meyer
ESEyal Sivan
Eyal Sivan
YYYoav Yinon
Yoav Yinon
Key message Laboratory characteristics of SARS-CoV-2 infection did not differ between pregnant and non-pregnant women. A trend of lower lymphocyte count was observed in the pregnant women group Purpose Laboratory abnormalities, which characterize SARS-CoV-2 infection have been identified, nevertheless, data concerning laboratory characteristics of pregnant women with SARS-CoV-2 are limited. The aim of this study is to evaluate the laboratory characteristics of pregnant compared to non-pregnant women with SARS-CoV-2 infection. Methods A retrospective cohort study of all pregnant women with SARS-CoV-2 who were examined at the obstetric emergency room in a tertiary medical center between March and April 2020. Patients were compared with non-pregnant women with SARS-CoV-2 matched by age, who were examined at the general emergency room during the study period. All patients were confirmed for SARS-CoV-2 on admission. Clinical characteristics and laboratory results were compared between the groups. Results Study group included 11 pregnant women with SARS-CoV-2, who were compared to 25 non-pregnant controls. Respiratory complaints were the most frequent reason for emergency room visit, and were reported in 54.5% and 80.0% of the pregnant and control groups, respectively (p = 0.12). White blood cells, hemoglobin, platelets, and liver enzymes counts were within the normal range in both groups. Lyphocytopenia was observed in 45.5% and 32% of the pregnant and control groups, respectively (p = 0.44). The relative lymphocyte count to WBC was significantly reduced in the pregnant group compared to the controls [13.6% (4.5–19.3) vs. 26.5% (15.7–29.9); p = 0.003]. C-reactive protein [20(5–41) vs. 14 (2–52) mg/dL; p = 0.81] levels were elevated in both groups but without significant difference between them. Conclusion Laboratory characteristics of SARS-CoV-2 infection did not differ between pregnant and non-pregnant women, although a trend of lower lymphocyte count was observed in the pregnant women group.

1 October 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AMAya Mohr-Sasson
Aya Mohr-Sasson
RMRonit Machtinger
Ronit Machtinger
RMRoy Mashiach
Roy Mashiach
ONOmer Nir
Omer Nir
YIYael Inbar
Yael Inbar
JRJaron Rabinovici
Jaron Rabinovici

26 April 2023 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
AMAya Mohr-Sasson
Aya Mohr-Sasson
TDTal Dadon
Tal Dadon
ABAriel Brandt
Ariel Brandt
MSMaya Shats
Maya Shats
MAMichal Axcelrod
Michal Axcelrod
RMRoy Mashiach
Roy Mashiach

13 April 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
AMAya Mohr-Sasson
Aya Mohr-Sasson
RHRoni Hochman
Roni Hochman
MAMatan Anteby
Matan Anteby
MSMaya Spira
Maya Spira
ECElias Castel
Elias Castel
ESEyal Sivan
Eyal Sivan